This report from Life Science Intelligence provides the latest market data for the Global Benign Prostatic Hyperplasia Implants Market. Information covered by this report includes:
· unit volumes & pricing forecast from 2019-2024
· analyses of the leading companies, and
· global market share analysis.
The global market for benign prostatic hyperplasia (BPH) implants was valued at an estimated $257 million in 2020 and is projected to increase at a CAGR (2020-2024) of 34.3%. This report covers permanent implants that are placed via the urethra to reduce or eliminate the urethral obstruction and the symptoms of BPH.
This report covers the impact of COVID-19 on the BPH implants market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors. The report provides insights into trends, drivers, and limiters of the BPH implants market, as well as highlights potential opportunities.
Procedures to relieve the symptoms of BPH were negatively impacted by the COVID-19 pandemic. The pandemic has affected elective surgical procedures tremendously as healthcare resources have been prioritized for the treatment of COVID-19 and other critical ill patients. As elective procedures begin to resume, procedures to treat BPH will slowly return to pre-COVID-19 levels.
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. The condition affects more than 30% of men above 50 years of age. The standard of care for BPH has been to manage symptoms pharmaceutically and surgical interventions such as transurethral resection of the prostate (TURP), transurethral needle ablation (TUNA), laser therapy, and others. Implants for the treatment of BPH represent a minimally invasive approach to managing symptoms without cutting, heating, or removing prostate tissue.